AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

@article{Katz2016AMG1,
  title={AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.},
  author={Lois Anne Katz and Nick Manamley and William J. Snyder and Michael G. Dodds and Natalia Agafonova and Justo Sierra-Johnson and Maria Luiza Cruz and Primal Kaur and Sunder Raj D Mudaliar and Philip Raskin and Reshma Kewalramani and Andrea Pellacani},
  journal={Diabetes, obesity & metabolism},
  year={2016},
  volume={18 2},
  pages={
          191-5
        }
}
Phase I studies have shown that AMG 151 activates glucokinase, a key enzyme in glucose homeostasis. The present randomized, placebo-controlled phase IIa study evaluated the dose-effect relationship of the glucokinase activator AMG 151 relative to placebo on fasting plasma glucose (FPG) in 236 patients (33-35 patients per arm) with type 2 diabetes treated with metformin. Patients received oral AMG 151 at 50, 100 or 200 mg twice daily, AMG 151 at 100, 200 or 400 mg once daily or matching placebo… CONTINUE READING
2
Twitter Mentions